H. Lundbeck, Lundbeck and Merck announce extension to Japan of alliance to develop and commercialise gaboxadol

H. Lundbeck A/S and Merck & Co., Inc. today announced an extension of their agreement for the exclusive development and commercialisation of the sleep disorder compound gaboxadol to Japan.